Evidence map›Paper›PMID 31781476›Full record

ArticleAnalytical cellular pathology (Amsterdam)2019

miR-590-3p and Its Downstream Target Genes in HCC Cell Lines.

Mennatallah Elfar, Asma Amleh

Open access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mennatallah ElfarBiotechnology Program, The American University in Cairo, Cairo, Egypt.ORCID https://orcid.org/0000-0001-7593-0518
Asma AmlehBiotechnology Program, The American University in Cairo, Cairo, Egypt.ORCID https://orcid.org/0000-0003-3613-3182
American University in Cairo · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miRNAs are small non-coding RNA sequences of 18-25 nucleotides. They can regulate different cellular pathways by acting on tumor suppressors, oncogenes, or both. miRNAs are mostly tissue-specific, and their expression varies depending on the cancer or the tissue in which they are found. hsa-miR-590-3p was found to be involved in several types of cancers. In this study, we identified potential downstream target genes of hsa-miR-590-3p computationally. Several bioinformatics tools and more than one approach were used to identify potential downstream target genes of hsa-miR-590-3p. CX3CL1, SOX2, N-cadherin, E-cadherin, and FOXA2 were utilized as potential downstream target genes of hsa-miR-590-3p. SNU449 and HepG2, hepatocellular carcinoma cell lines, were used to carry out various molecular techniques to further validate our

Indexed as

Genes, NeoplasmBase SequenceBiomarkers, TumorCadherinsCarcinoma, HepatocellularCell Line, TumorChemokine CX3CL1Gene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-betaHumansLiver NeoplasmsMesodermMicroRNAsRNA, MessengerSOXB1 Transcription FactorsVersicansBiomarkers, TumorCadherinsChemokine CX3CL1FOXA2 protein, humanHepatocyte Nuclear Factor 3-betaMicroRNAsMIRN590 microRNA, humanRNA, MessengerSOXB1 Transcription FactorsVCAN protein, humanVersicansVimentin

Identifiers

PMID31781476
PMCPMC6875279
OpenAlexW2983412005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.